trelstar and Leukemia

To compare the rate of premature ovarian failure (POF) after stem cell transplantation (SCT) in young women receiving GnRH-agonist (GnRH-a) in conjunction with gonadotoxic chemotherapy.. Prospective, nonrandomized study.. Tertiary university hospital.. Ninety-five women received conditioning chemotherapy, with or without GnRH-a before SCT. Complete information was available for only 83 patients.. Conditioning chemotherapy, with or without GnRH-a before SCT.. Cyclic ovarian function (COF) or POF after SCT.. There were no significant differences in age, chemotherapy treatment, or diagnoses between the study and control groups. In the GnRH-a group, 38.3% (18/47) patients resumed COF, compared with 11.1% (4/36) for patients who did not receive GnRH-a. Patients who resumed COF were on average 3.7 years (median, 3 years) younger at the time of transplantation than those who experienced POF. GnRH-a had a significant effect on long-term COF in patients with lymphomas (66.7% [14/21] for GnRH-a group vs. 18.2% [2/11] for control) but not for leukemia patients.. GnRH-a cotreatment in conjunction with conditioning chemotherapy before SCT may significantly decrease the gonadotoxicity and POF from 82% to 33% in lymphoma but not in leukemia patients.

Topics: Adult; Case-Control Studies; Chi-Square Distribution; Female; Fertility Agents, Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Israel; Leukemia; Lymphoma; Ovary; Primary Ovarian Insufficiency; Prospective Studies; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Treatment Outcome; Triptorelin Pamoate